eli lilly retatrutide study Lilly's next act in diabetes and obesity retatrutide #elililly #retatrutide #weightloss #obesitycare
Description
These data suggest that a mGIPR-Ab/GLP-1 peptideantibody conjugate may act on a different population of cells or via distinct molecular mechanism(s) compared to GIPR agonists like tirzepatide
Such studies are continuing for patients without cancer (NCT05786521, NCT06811324, and NCT06497595) (80) and are being initiated in the context of cancer (NCT06751589)
At NuLife Health & Wellness, we emphasize personalized consultations to determine the appropriateness of semaglutide for each individual
Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies
Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression
The window, as I see it, is 6 months
